443 Studies Now Enrolling
A Phase II Multicenter, Randomized, Double-blind, Placebo-Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subject with Moderate to Severe Active Systemic Lupus Erythematosus
A study for patients with Systemic Lupus Erythematosus using study drug ALX-0061
| Sponsor: | Ablynx |
| Enrolling: | Male and Female Patients |
| Study Length: | 1 Years |
| IRB Number: | AAAP7757 |
| U.S. Govt. ID: | NCT02437890 |
| Contact: | Anca Askanase: 212-305-0856 / ada20@cumc.columbia.edu |
Additional Study Information:
The goal of this study is to test a new lupus drug. This drug interrupts the function of a chemical in the body called IL-6, and IL-6 may be overactive in people with lupus. ALX-0061 is a study drug that will be administered subcutaneously to subjects with moderate to severe active, seropositive Systemic Lupus Erythematosus (SLE) compared to placebo.
This study is closed
